SESSION 9: MANTLE CELL LYMPHOMA
A SIMPLE EPIGENETIC SIGNATURE DEFINES TWO BIOLOGIC GROUPS OF MANTLE CELL LYMPHOMA abstract
M. M. Bühler, M. Kulis, M. Duran-Ferrer, G. Clot, et al.
The study authors conclude that their study highlights the stability and applicability of a methylation signature to classify MCL subtypes. Their analysis of the methylation signature in an extended series of cases is currently ongoing and will allow them to determine the prognostic significance of the epigenetic subtype of MCL. They note that this epigenetic signature applicable to any type of clinical samples may represent a novel and accurate tool for the differential diagnosis of cMCL and nnMCL in clinical routine.
A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) abstract
S. Ferrero, R. Moia, L. Cascione, G. M. Zaccaria, et al.
The study authors conclude that the inclusion of 4CNVs into the MIPI-g allowed the development of a complete molecular model that improved the stratification in MCL, enriching the HR group of patients, primary refractory or destined to an early relapse after high dose chemotherapy and ASCT.
EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL-2015 STUDY abstract
E. Giné, F. De la Cruz, A. Jiménez Ubieto, J. López Jiménez, et al.
The study authors conclude that in indolent clinical forms of MCL frontline ibrutinib in combination with rituximab has high efficacy, including undetectable MRD in the majority of cases, with a predictable toxicity profile.
THE COMBINATION OF VENETOCLAX, LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA INDUCES HIGH RESPONSE RATES AND MRD UNDETECTABILITY. abstract
T. J. Phillips, D. Bond, S. Devata, A. Danilov, et al.
The study authors interim results show that at the MTD the combination of V 400 mg daily, L 20 mg, with Rituximab is safe with a manageable toxicity profile and a high ORR and MRD - in patients with newly diagnosed MCL. Safety data is consistent with the AE profile noted for each drug without any unexpected or unique AEs. Updated results including BH3 profiling are presented at the meeting.
SAKK 36/13 - IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK abstract
U. Novak, M. Fehr, S. Schär, M. Dreyling, et al.
The study authors conclude that the combination of Ibrutinib and Bortezomib shows significant and durable efficacy in relapsed mantle-cell lymphoma, importantly also in patients with high-risk features. They note that in this setting, this regimen is a rational comparator regimen for a future phase III trial.
INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY abstract
J. P. Sharman, J. M. Melear, A. Yacoub, S. R. Fanning, et al.
The study authors conclude thatlenalidomide + rituximab (R2) is an active and tolerated regimen with durable responses among patients with R/R MCL and mostly naive to Bruton tyrosine kinase inhibitor therapy.